WASHINGTON STATE CONVENTION CENTER

Seattle, Washington
March 4–7, 2019

 

Conference Dates and Location: 
February 22–25, 2016 | Boston, Massachusetts
Abstract Number: 
440

Nevirapine Dosing for Treatment in the First Month of Life

Author(s): 

Mark Mirochnick1; Karin Nielsen-Saines2; Jose H. Pilotto3; Philippa Musoke4; Avinash Shetty5; Katherine Luzuriaga6; Edmund Capparelli7
1Boston Univ Sch of Med, Boston, MA, USA;2Univ of California Los Angeles, Los Angeles, CA, USA;3Hosp Geral de Nova Iguaçu, Rio de Janeiro, Brazil;4Makerere Univ, Kampala, Uganda;5Wake Forest Univ, Winston Salem, NC, USA;6Univ of Massachusetts Med Sch, Worcester, MA, USA;7Univ of California San Diego, San Diego, CA, USA

Abstract Body: 

NVP clearance (CL) is low in term neonates and further decreased in preterm infants due to immaturity in CYP2B6 and CYP3A4 activity.  NVP autoinduces its own CL but the extent of autoinduction on immature enzyme systems is unknown.  While pharmacokinetic (PK) studies have been done to determine NVP dosing regimens for treatment of HIV infection (trough conc target 3.0 ug/mL) in infants after 1 month of life, NVP PK studies under age 1 month are limited to evaluations of dosing regimens for prophylaxis against HIV infection (trough conc target 0.1 ug/mL).  Population modeling of these PK data and simulations can be used to evaluate proposed NVP dosing regimens to achieve treatment target conc in term and late preterm infants (34-37 weeks gestation) from birth through 6 months of life.

We developed a NVP population PK model using NONMEM that incorporated data from 192 infants (1121 plasma NVP conc) from US, Africa and Brazil under age 1 yr in 5 PACTG or HPTN protocols. Prematurity effects were estimated from the published literature (de Waal 2014).  Dosing regimens from birth through 6 months of age were evaluated using simulations. Simulated NVP doses included 6 mg/kg BID for term infants and 4mg/kg BID for 1 week followed by 6 mg/kg BID for late preterm infants.  Proposed PK target was NVP trough conc > 3.0 ug/mL.

A one compartment model with first order absorption was used. CL was scaled allometrically and volume of distribution (Vd) was scaled linearly for weight. CL was modeled to mature exponentially with age.  Autoinduction of CL was modeled as a linear function of dose. The effects of prematurity and maturation of CYP2B6 and CYP3A4 activity on NVP CL were imputed from published studies.  Ttypical CL (L/hr/kg) in term infants increased by nearly 6 fold from birth to 6 months due to maturation and by an additional 79% due to induction.  Final simulations used term infant doses of 6 mg/kg BID and late preterm infant doses of 4mg/kg BID for 1 week followed by 6 mg/kg BID.  In these simulations, the dosing regimens achieved NVP targ

NVP CL is low immediately after birth and increases dramatically over the 1st months of life.  Appropriate NVP dosing regimens in neonates must take into account the impact of maturation, auto-induction and prematurity on NVP CL.  The dosing regimens supported by these simulations and NVP PK in preterm infants are being studied in the IMPAACT 1115 and 1106 protocols.

Session Number: 
P-H2
Session Title: 
Clinical Pharmacology: Pregnancy, Pediatrics, and Predictions
Presenting Author: 
Mark Mirochnick
Presenter Institution: 
Boston University School of Medicine
Poster: